Data gathered: October 23
AI Stock Analysis - Catalyst Pharmaceuticals (CPRX)
Analysis generated August 11, 2025. Powered by Chat GPT.
Catalyst Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of unique and innovative treatments for rare neurological diseases and disorders. Their flagship product, Firdapse, is a significant treatment targeted at Lambert-Eaton Myasthenic Syndrome (LEMS). The company seeks to leverage its proprietary drug development and sales platforms to expand its portfolio, offering new hope to patients with debilitating ailments.
Stock Alerts - Catalyst Pharmaceuticals (CPRX)
 |
Catalyst Pharmaceuticals | October 9 Business Outlook among employees is down by 33% over the last month. |
|
Catalyst Pharmaceuticals | October 9 Employee Rating is up by 12.5% over the last month. |
|
Catalyst Pharmaceuticals | October 1 Price is up by 7.3% in the last 24h. |
|
Catalyst Pharmaceuticals | September 12 Insider Alert: Elsbernd Brian is continuing selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Catalyst Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 93 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 90 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | 2 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 69 | Sign up | Sign up | Sign up |
| Facebook Followers | 3,122 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 15,798 | Sign up | Sign up | Sign up |
| Twitter Followers | 868 | Sign up | Sign up | Sign up |
| Twitter Mentions | 49 | Sign up | Sign up | Sign up |
| X Mentions | 2 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 67 | Sign up | Sign up | Sign up |
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.
| Price | $20.73 |
| Target Price | Sign up |
| Volume | 1,040,000 |
| Market Cap | $2.62B |
| Year Range | $19.13 - $26.31 |
| Dividend Yield | 0% |
| PE Ratio | 12.99 |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025October 22 - GlobeNewswire |
|
 |
Catalyst Pharmaceuticals Shares Climb as New Drug Developments Spark Fresh Valuation DebateOctober 13 - Yahoo |
|
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-TermOctober 9 - Yahoo |
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific ConferencesOctober 9 - GlobeNewswire |
|
|
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-TermOctober 7 - Yahoo |
|
What do Analysts Think About Catalyst Pharmaceuticals (CPRX)?October 7 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 147M | 30M | 117M | 52M | 79M | 0.680 |
| Q1 '25 | 141M | 18M | 124M | 57M | 73M | 0.680 |
| Q4 '24 | 142M | 22M | 120M | 56M | 72M | 0.700 |
| Q3 '24 | 129M | 19M | 109M | 44M | 51M | 0.350 |
| Q2 '24 | 123M | 25M | 98M | 41M | 54M | 0.330 |
Insider Transactions View All
| Elsbernd Brian filed to sell 271,039 shares at $20.3. September 10 '25 |
| Elsbernd Brian filed to sell 188,564 shares at $19.5. September 5 '25 |
| Elsbernd Brian filed to sell 188,564 shares at $20.1. September 5 '25 |
| Tierney David S filed to sell 379,620 shares at $20.2. August 28 '25 |
| Daly Richard J filed to sell 226,794 shares at $20.6. August 28 '25 |
Similar companies
Read more about Catalyst Pharmaceuticals (CPRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, news mentions, customer reviews & business outlook.
What is the Market Cap of Catalyst Pharmaceuticals?
The Market Cap of Catalyst Pharmaceuticals is $2.62B.
What is Catalyst Pharmaceuticals' PE Ratio?
As of today, Catalyst Pharmaceuticals' PE (Price to Earnings) ratio is 12.99.
What is the current stock price of Catalyst Pharmaceuticals?
Currently, the price of one share of Catalyst Pharmaceuticals stock is $20.73.
How can I analyze the CPRX stock price chart for investment decisions?
The CPRX stock price chart above provides a comprehensive visual representation of Catalyst Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Catalyst Pharmaceuticals shares. Our platform offers an up-to-date CPRX stock price chart, along with technical data analysis and alternative data insights.
Does CPRX offer dividends to its shareholders?
As of our latest update, Catalyst Pharmaceuticals (CPRX) does not offer dividends to its shareholders. Investors interested in Catalyst Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Catalyst Pharmaceuticals?
Some of the similar stocks of Catalyst Pharmaceuticals are Amgen, Gilead Sciences, Inovio Pharmaceuticals, Anavex Life Sciences, and BridgeBio Pharma.
.
